Dyne Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Dyne Therapeutics CEO'su John Cox, Mar2024 tarihinde atandı, in görev süresi 1.17 yıldır. in toplam yıllık tazminatı $ 20.84M olup, şirket hissesi ve opsiyonları dahil olmak üzere 2.6% maaş ve 97.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.037% ine doğrudan sahiptir ve bu hisseler $ 491.66K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.7 yıl ve 5.5 yıldır.

Anahtar bilgiler

John Cox

İcra Kurulu Başkanı

US$20.8m

Toplam tazminat

CEO maaş yüzdesi	2.58%
CEO görev süresi	1.2yrs
CEO sahipliği	0.04%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	5.5yrs

Son yönetim güncellemeleri

Recent updates

Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker

Mar 13

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Feb 28

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Aug 14

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

May 21

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

May 04

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Mar 05

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dec 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

Aug 09

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Mar 26

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dec 10

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Aug 26

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Jul 12

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Jul 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 05

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Jan 12

We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Sep 29

CEO Tazminat Analizi

John Cox'un ücretlendirmesi Dyne Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2025	n/a	n/a	-US$367m
Dec 31 2024	US$21m	US$537k	-US$317m

Tazminat ve Piyasa: John 'nin toplam tazminatı ($USD 20.84M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 6.07M ).

Tazminat ve Kazançlar: John şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

John Cox (61 yo)

1.2yrs

Görev süresi

US$20,839,617

Tazminat

Mr. John G. Cox, M.B.A. serves as Chief Executive Officer, President and Director at Dyne Therapeutics, Inc. from March 2024. He also serves as Atlas Advisor at Atlas Venture L.P. since 2024. He serves as...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
John Cox	CEO, President & Director	1.2yrs	US$20.84m	0.037% $ 491.7k
Oxana Beskrovnaya	Chief Innovation Officer	less than a year	US$3.84m	0.038% $ 503.1k
Johanna Friedl-Naderer	Chief Commercial Officer	less than a year	US$8.54m	0.0019% $ 25.9k
Douglas Kerr	Chief Medical Officer	less than a year	US$8.09m	0.0015% $ 19.4k
Erick Lucera	CFO, Principal Financial Officer & Principal Accounting Officer and Treasurer	less than a year	Veri yok	Veri yok
Rajesh Manchanda	Chief Technical Officer	less than a year	Veri yok	Veri yok
James Bilotta	Chief Digital & Information Officer	less than a year	Veri yok	Veri yok
Ranjan Batra	Chief Scientific Officer	less than a year	Veri yok	Veri yok
Daniel Wilson	Senior VP & Head of Legal	4.9yrs	Veri yok	Veri yok
Lucia Celona	Chief Human Resource Officer	less than a year	Veri yok	Veri yok
Debra Feldman	Chief Regulatory Affairs Officer	5yrs	Veri yok	Veri yok
Ashish Dugar	Chief Medical Affairs Officer	4.3yrs	Veri yok	Veri yok

0.7yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: DYN 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.7 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
John Cox	CEO, President & Director	1.2yrs	US$20.84m	0.037% $ 491.7k
Sudhir Agrawal	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Edward Hurwitz	Independent Director	6.5yrs	US$546.85k	0% $ 0
David Lubner	Independent Director	5.2yrs	US$560.85k	0.047% $ 627.4k
Jason Rhodes	Independent Chairman	7.4yrs	US$579.85k	0% $ 0
Dirk Kersten	Independent Director	6.5yrs	US$559.35k	0% $ 0
Francesco Muntoni	Member of Scientific Advisory Board	4.8yrs	Veri yok	Veri yok
Louis Kunkel	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Nancy Andrews	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Catherine Stehman-Breen	Independent Director	5.9yrs	US$554.35k	0.079% $ 1.0m
Charles Thornton	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jeffrey Statland	Member of Scientific Advisory Board	5yrs	Veri yok	Veri yok

5.5yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: DYN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.5 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/15 07:29
Gün Sonu Hisse Fiyatı	2025/05/14 00:00
Kazançlar	2025/03/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Dyne Therapeutics, Inc. 17 Bu analistlerden 13, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Brian Skorney	Baird
Konstantinos Biliouris	BMO Capital Markets Equity Research
Keay Nakae	Chardan Capital Markets, LLC

Dyne Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Dyne Therapeutics, Inc., Annual General Meeting, May 30, 2025

CEO, President & Director recently bought US$1.1m worth of stock

Dyne Therapeutics, Inc Announces Management Changes

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

Recent updates

Dyne Therapeutics, Inc., Annual General Meeting, May 30, 2025

Dyne Therapeutics, Inc. Announces New Long-Term Clinical Data from Phase 1/2 Deliver Trial of Dyne-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker

New major risk - Shareholder dilution

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dyne Therapeutics to Present Data from the Ongoing DELIVER Clinical Trial in Duchenne Muscular Dystrophy At Upcoming Presentations At the 2025 MDA Clinical & Scientific Conference

Dyne Therapeutics: Moving Forward On 2 Key Fronts

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

New minor risk - Share price stability

Dyne Therapeutics, Inc. Announces New Clinical Data from Its Ongoing Phase 1/2 Achieve Trial of Dyne-10 in Patients with Myotonic Dystrophy Type 1 (DM1)

New minor risk - Insider selling

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

CEO, President & Director recently bought US$1.1m worth of stock

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Dyne Therapeutics, Inc Announces Management Changes

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Price target increased by 8.9% to US$50.00

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $325.5 million.

New major risk - Shareholder dilution

Chief Scientific Officer notifies of intention to sell stock

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dyne Therapeutics, Inc., Annual General Meeting, May 22, 2024

Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes

CEO, President & Director recently sold US$223k worth of stock

Chief Operating Officer recently sold US$725k worth of stock

Price target increased by 8.3% to US$37.56

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

CEO, President & Director notifies of intention to sell stock

Chief Business Officer exercised options and sold US$476k worth of stock

New major risk - Shareholder dilution

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

Chief Business Officer notifies of intention to sell stock

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Chief Operating Officer notifies of intention to sell stock

New major risk - Financial position

CEO, President & Director notifies of intention to sell stock

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

New major risk - Financial position

Insufficient new directors

CEO, President & Director recently sold US$618k worth of stock

CEO, President & Director notifies of intention to sell stock

Dyne Therapeutics, Inc. Announces Resignation of Dr. Lawrence Klein as Board Member

Insufficient new directors

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Price target increased by 9.6% to US$28.50

Insider exercised options and sold US$133k worth of stock

Insider notifies of intention to sell stock

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dyne Therapeutics, Inc. Receives Fda Fast Track Designation for Dyne-251 for the Treatment of Duchenne Muscular Dystrophy

CEO, President & Director exercised options and sold US$2.4m worth of stock

Dyne Therapeutics, Inc. Presents Preclinical Data from Its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 At World Muscle Society 2022 Congress

Dyne Therapeutics, Inc. Prioritizes its Focus and Resources on its Clinical Programs, DYNE-101 in DM1 and DYNE-251 in DMD

Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics, Inc. Appoints Francesco Bibbiani as Senior Vice President, Head of Development

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Dyne Therapeutics, Inc. Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research

High number of new directors

Price target decreased to US$24.67

Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1